Showing results (1-10 of 100) with videos related to
Sort By:
Pageof 10
Cellular Immunology|January 21, 2021
Reactive myelopoiesis and the onset of myeloid-mediated immune suppression: Implications for adoptive cell therapyPatrick Innamarato, Shari Pilon-ThomasJournal of Immunotherapy (Hagerstown, Md. : 1997)|April 9, 2008
Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanomaNobusada Koike, Shari Pilon-Thomas, James J MuléBiorxiv : the Preprint Server for Biology|December 3, 2025
Rethinking the seven-day treatment-free interval in T-cell engager therapy using agent-based modelingNina Obertopp, Matthew Froid, Shari Pilon-Thomas, et al.Neoplasia (New York, N.Y.)|April 21, 2022
Mathematical modeling of radiotherapy and its impact on tumor interactions with the immune systemRebecca Anne Bekker, Sungjune Kim, Shari Pilon-Thomas, et al.Frontiers in Immunology|June 15, 2026
Artificial intelligence for optimization of immunotherapy: current applications and transformative potentialAli Tarhini, Palak Dave, Shari Pilon-Thomas, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 3, 2010
Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanomaShari Pilon-Thomas, Amy Mackay, Nasreen Vohra, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 25, 2003
Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccinesMarie P Piechocki, Ye-Shih Ho, Shari Pilon, et al.Cytotherapy|December 5, 2018
Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing processEmily L Hopewell, Cheryl Cox, Shari Pilon-Thomas, et al.Oncoimmunology|November 21, 2015
Triggering co-stimulation directly in melanoma tumor fragments drives CD8+ tumor-infiltrating lymphocyte expansion with improved effector-memory propertiesJessica Ann Chacon, Amod A Sarnaik, Shari Pilon-Thomas, et al.Pageof 10